Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Liquidia Corporation

LQDANASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Sep 15, 2026Accepted Sep 15, 2026, 4:30 PM EDTFiling CIK 1819576Accession 0001104659-26-107942
Share

Structured filing — 4

tm2625466-1_4seq1.xml

Open full document ↗

Filing details

Report period
2026-09-11
Issuer
Liquidia Corp
Issuer CIK
0001819576
Trading symbol
LQDA

Reporting owner 1

Name
SINGH RAMAN
Reporting owner CIK
0001747589
Relationship
Director
Address
419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC, 27560

Non-derivative transactions

Non-derivative transactions · 5 reported rows
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnership
Common Stock2026-09-11M · Form 4556A8.6345,193[F1]D
Common Stock2026-09-11M · Form 48,468A9.305553,661[F1]D
Common Stock2026-09-11S · Form 4[F2]9,024D68.6181[F3]44,637[F1]D
Common Stock2026-09-14M · Form 48,468A9.305553,105[F1]D
Common Stock2026-09-14S · Form 4[F2]8,468D66.1644,637[F1]D
Table key
M · Form 4
Exempt derivative exercise or conversion under Rule 16b-3
A
Acquired
D
Direct
S · Form 4
Sale on the market or privately

Derivative transactions

Derivative transactions · 3 reported rows
SecurityConversion / exercise price (USD)Transaction dateCodeAmountA / DPrice (USD)ExercisableExpiresUnderlying securityUnderlying sharesOwned afterOwnership
Non-Qualified Stock Option (right to buy)8.632026-09-11M · Form 4556D02026-06-19[F4]2033-06-19Common Stock5560D
Non-Qualified Stock Option (right to buy)9.30552026-09-11M · Form 48,468D02021-03-07[F5]2028-03-07Common Stock8,4688,468D
Non-Qualified Stock Option (right to buy)9.30552026-09-14M · Form 48,468D02021-03-07[F5]2028-03-07Common Stock8,4680D
Table key
M · Form 4
Exempt derivative exercise or conversion under Rule 16b-3
D
Direct

Footnotes

F1
Includes 5,882 restricted stock units granted to the Reporting Person on June 16, 2026, none of which have vested as of the date of this Form 4.↩ 1↩ 2↩ 3↩ 4↩ 5
F2
Represents the subsequent sale of the underlying shares from the exercise of stock options reported on this Form 4.↩ 1↩ 2
F3
Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $68.60 to $68.70. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.↩ 1
F4
The option vested in 36 equal monthly installments and became fully vested on June 19, 2026.↩ 1
F5
The option vested in 36 equal monthly installments and became fully vested on March 7, 2021.↩ 1↩ 2

Signature 1

Signed
/s/ Raman Singh
Date
2026-09-15

Company context

Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of YUTREPIA® (treprostinil) inhalation powder, approved for the treatment of pulmonary arterial hypertension (PAH), and in development for Raynaud’s phenomenon secondary to systemic sclerosis (SSc-RP). The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice daily via a next-generation nebulizer to treat PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD). To learn more about Liquidia, please visit www.liquidia.com.

Current securities

Recent company filings

  1. Results of Operations and Financial Condition · Other EventsNov 10, 2026
  2. 10-Q filingNov 10, 2026
  3. 4 filingOct 28, 2026
  4. Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Regulation FD Disclosure · Other EventsOct 14, 2026
  5. 4 filingOct 13, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.